BioLife Solutions, Inc.
BLFS
$25.65
-$0.26-1.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.94% | 29.88% | 44.21% | 29.69% | -32.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.94% | 29.88% | 44.21% | 29.69% | -32.57% |
| Cost of Revenue | 38.11% | 31.70% | 22.38% | 23.30% | -64.27% |
| Gross Profit | 24.43% | 28.96% | -7.38% | 35.85% | 19.80% |
| SG&A Expenses | 19.72% | 10.37% | 2.17% | -5.07% | -32.06% |
| Depreciation & Amortization | 3.66% | 2.03% | 100.49% | -30.64% | -51.42% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.27% | 15.79% | 44.76% | -0.58% | -48.46% |
| Operating Income | 14.09% | 63.03% | -46.07% | 82.17% | 88.69% |
| Income Before Tax | -182.64% | 86.36% | -86.42% | 88.97% | -0.78% |
| Income Tax Expenses | 12,500.00% | -17.65% | 43.78% | -124.35% | -50.00% |
| Earnings from Continuing Operations | -184.86% | 86.00% | -85.56% | 89.22% | -0.76% |
| Earnings from Discontinued Operations | -- | -- | 140.62% | -- | -223.84% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.56% | 95.62% | 183.30% | 94.15% | -103.15% |
| EBIT | 14.09% | 63.03% | -46.07% | 82.17% | 88.69% |
| EBITDA | -75.38% | 116.32% | -44.30% | 113.61% | 112.44% |
| EPS Basic | 26.42% | 95.78% | 180.04% | 94.48% | -91.82% |
| Normalized Basic EPS | 87.62% | 86.76% | -43.75% | 81.79% | 87.85% |
| EPS Diluted | 26.42% | 95.78% | 176.93% | 94.48% | -91.82% |
| Normalized Diluted EPS | 87.62% | 86.76% | -45.38% | 81.79% | 87.85% |
| Average Basic Shares Outstanding | 3.90% | 3.75% | 4.07% | 5.98% | 5.90% |
| Average Diluted Shares Outstanding | 3.90% | 3.75% | 7.16% | 5.98% | 5.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |